UA79730C2 - Composition with sustained release of thiazolidine dione derivative and its use for the treatment of type 2 diabetes mellitus and conditions associated with diabetes mellitus - Google Patents

Composition with sustained release of thiazolidine dione derivative and its use for the treatment of type 2 diabetes mellitus and conditions associated with diabetes mellitus Download PDF

Info

Publication number: UA79730C2
Authority: UA; Ukraine
Prior art keywords: concentration; pharmaceutical composition; dione; methyl; ethoxy
Prior art date: 1998-11-12

Application number

UA2001053164A

Other languages

English (en)

Ukrainian (uk)

Inventor

Lisa Benincosa

William Jusko

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-11-12

Filing date

1999-11-12

Publication date

2007-07-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10842389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA79730(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-11-12 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2007-07-25 Publication of UA79730C2 publication Critical patent/UA79730C2/uk

Links

238000013268 sustained release Methods 0.000 title claims abstract description 10
239000012730 sustained-release form Substances 0.000 title claims abstract description 10
238000011282 treatment Methods 0.000 title claims description 13
208000001072 type 2 diabetes mellitus Diseases 0.000 title claims description 11
239000000203 mixture Substances 0.000 title description 27
206010012601 diabetes mellitus Diseases 0.000 title description 15
150000001467 thiazolidinediones Chemical class 0.000 title description 4
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
150000003839 salts Chemical class 0.000 claims abstract description 10
239000003937 drug carrier Substances 0.000 claims abstract description 6
239000012453 solvate Substances 0.000 claims abstract description 6
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 10
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
239000002775 capsule Substances 0.000 claims description 3
229940126601 medicinal product Drugs 0.000 claims description 3
150000002688 maleic acid derivatives Chemical class 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
239000013543 active substance Substances 0.000 abstract description 7
239000003814 drug Substances 0.000 abstract description 4
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 description 69
210000002381 plasma Anatomy 0.000 description 60
229940122355 Insulin sensitizer Drugs 0.000 description 44
238000000034 method Methods 0.000 description 28
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 22
239000008103 glucose Substances 0.000 description 19
235000002639 sodium chloride Nutrition 0.000 description 9
229940123464 Thiazolidinedione Drugs 0.000 description 8
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 8
206010022489 Insulin Resistance Diseases 0.000 description 7
239000003472 antidiabetic agent Substances 0.000 description 7
239000001768 carboxy methyl cellulose Substances 0.000 description 7
230000004044 response Effects 0.000 description 7
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
229920002472 Starch Polymers 0.000 description 5
239000008107 starch Substances 0.000 description 5
235000019698 starch Nutrition 0.000 description 5
229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
229940125708 antidiabetic agent Drugs 0.000 description 4
235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
239000008112 carboxymethyl-cellulose Substances 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
-1 glidants Substances 0.000 description 4
230000006872 improvement Effects 0.000 description 4
208000017169 kidney disease Diseases 0.000 description 4
239000007788 liquid Substances 0.000 description 4
238000007911 parenteral administration Methods 0.000 description 4
230000003285 pharmacodynamic effect Effects 0.000 description 4
229960005095 pioglitazone Drugs 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
235000010443 alginic acid Nutrition 0.000 description 3
229920000615 alginic acid Polymers 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
238000009826 distribution Methods 0.000 description 3
239000000945 filler Substances 0.000 description 3
238000011049 filling Methods 0.000 description 3
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000009467 reduction Effects 0.000 description 3
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
235000019333 sodium laurylsulphate Nutrition 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
239000000725 suspension Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
239000006188 syrup Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
229940033134 talc Drugs 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 3
229960001641 troglitazone Drugs 0.000 description 3
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
229920001353 Dextrin Polymers 0.000 description 2
239000004375 Dextrin Substances 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
206010018429 Glucose tolerance impaired Diseases 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
229920000161 Locust bean gum Polymers 0.000 description 2
239000005913 Maltodextrin Substances 0.000 description 2
229920002774 Maltodextrin Polymers 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
239000000205 acacia gum Substances 0.000 description 2
230000009471 action Effects 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
HZVVJJIYJKGMFL-UHFFFAOYSA-N almasilate Chemical compound O.[Mg+2].[Al+3].[Al+3].O[Si](O)=O.O[Si](O)=O HZVVJJIYJKGMFL-UHFFFAOYSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
229940075614 colloidal silicon dioxide Drugs 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
235000019425 dextrin Nutrition 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000003925 fat Substances 0.000 description 2
235000019197 fats Nutrition 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
230000002641 glycemic effect Effects 0.000 description 2
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 2
229940046813 glyceryl palmitostearate Drugs 0.000 description 2
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
235000010420 locust bean gum Nutrition 0.000 description 2
239000000711 locust bean gum Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000011976 maleic acid Substances 0.000 description 2
229940035034 maltodextrin Drugs 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
229920000193 polymethacrylate Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
229920003124 powdered cellulose Polymers 0.000 description 2
235000019814 powdered cellulose Nutrition 0.000 description 2
201000009104 prediabetes syndrome Diseases 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
235000021251 pulses Nutrition 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000004088 simulation Methods 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
229940123208 Biguanide Drugs 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
244000166652 Cymbopogon martinii Species 0.000 description 1
235000018793 Cymbopogon martinii Nutrition 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
208000002249 Diabetes Complications Diseases 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
208000002705 Glucose Intolerance Diseases 0.000 description 1
102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
240000000018 Gnetum gnemon Species 0.000 description 1
235000008612 Gnetum gnemon Nutrition 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
206010060378 Hyperinsulinaemia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
241000692870 Inachis io Species 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
229940122199 Insulin secretagogue Drugs 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
102000016267 Leptin Human genes 0.000 description 1
108010092277 Leptin Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000001280 Prediabetic State Diseases 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
125000002015 acyclic group Chemical group 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000011805 ball Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
229950009226 ciglitazone Drugs 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
208000028208 end stage renal disease Diseases 0.000 description 1
201000000523 end stage renal failure Diseases 0.000 description 1
229950002375 englitazone Drugs 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
150000002194 fatty esters Chemical class 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
208000004104 gestational diabetes Diseases 0.000 description 1
206010061989 glomerulosclerosis Diseases 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
239000008187 granular material Substances 0.000 description 1
210000004013 groin Anatomy 0.000 description 1
230000003760 hair shine Effects 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000000055 hyoplipidemic effect Effects 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000003451 hyperinsulinaemic effect Effects 0.000 description 1
201000008980 hyperinsulinism Diseases 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical group OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
229940039781 leptin Drugs 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
235000019793 magnesium trisilicate Nutrition 0.000 description 1
229940099273 magnesium trisilicate Drugs 0.000 description 1
229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
150000002689 maleic acids Chemical class 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
201000009925 nephrosclerosis Diseases 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000009520 phase I clinical trial Methods 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
201000010065 polycystic ovary syndrome Diseases 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
235000007686 potassium Nutrition 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000007789 sealing Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
238000003307 slaughter Methods 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000020354 squash Nutrition 0.000 description 1
229940071117 starch glycolate Drugs 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
229960004274 stearic acid Drugs 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
235000019731 tricalcium phosphate Nutrition 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
229940057977 zinc stearate Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Diabetes (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

UA2001053164A 1998-11-12 1999-11-12 Composition with sustained release of thiazolidine dione derivative and its use for the treatment of type 2 diabetes mellitus and conditions associated with diabetes mellitus UA79730C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9824893.3A GB9824893D0 (en)	1998-11-12	1998-11-12	Novel method of treatment
PCT/US1999/026746 WO2000027341A2 (en)	1998-11-12	1999-11-12	Novel method of treatment

Publications (1)

Publication Number	Publication Date
UA79730C2 true UA79730C2 (en)	2007-07-25

Family

ID=10842389

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2001053164A UA79730C2 (en)	1998-11-12	1999-11-12	Composition with sustained release of thiazolidine dione derivative and its use for the treatment of type 2 diabetes mellitus and conditions associated with diabetes mellitus

Country Status (40)

Country	Link
EP (2)	EP1759698A1 (de)
JP (1)	JP2003521455A (de)
KR (2)	KR20010080440A (de)
CN (3)	CN1771943A (de)
AP (2)	AP2005003432A0 (de)
AR (2)	AR029317A1 (de)
AT (1)	ATE366573T1 (de)
AU (1)	AU768303B2 (de)
BG (2)	BG110061A (de)
BR (1)	BR9915284A (de)
CA (1)	CA2350425C (de)
CO (1)	CO5150158A1 (de)
CY (1)	CY1106892T1 (de)
CZ (1)	CZ299801B6 (de)
DE (1)	DE69936533T2 (de)
DK (1)	DK1135128T3 (de)
DZ (1)	DZ2938A1 (de)
EA (2)	EA200700968A1 (de)
ES (1)	ES2289833T3 (de)
GB (1)	GB9824893D0 (de)
HK (1)	HK1041202B (de)
HR (1)	HRP20010344B1 (de)
HU (1)	HUP0104262A3 (de)
IL (1)	IL143088A0 (de)
MA (1)	MA26759A1 (de)
MY (1)	MY128347A (de)
NO (1)	NO328391B1 (de)
NZ (1)	NZ527132A (de)
OA (1)	OA12193A (de)
PE (1)	PE20001239A1 (de)
PL (1)	PL349421A1 (de)
PT (1)	PT1135128E (de)
RS (1)	RS50130B (de)
SK (1)	SK286357B6 (de)
TR (1)	TR200101348T2 (de)
TW (1)	TWI234456B (de)
UA (1)	UA79730C2 (de)
UY (2)	UY25797A1 (de)
WO (1)	WO2000027341A2 (de)
ZA (1)	ZA200103793B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY125516A (en)	1999-11-16	2006-08-30	Smithkline Beecham Plc	Novel composition based on thiazolidinedione and metformin and use
ES2259736T3 (es) *	2001-12-21	2006-10-16	Smithkline Beecham Corporation	Regimen de dosificacion para activadores de ppar-gamma-.
WO2012074375A1 (en) *	2010-12-01	2012-06-07	N.V. Nutricia	Prevention or treatment of overweight and obesity in type 2 diabetic patients

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5522636A (en) *	1978-08-04	1980-02-18	Takeda Chem Ind Ltd	Thiazoliding derivative
JPS5697277A (en) *	1980-01-07	1981-08-05	Takeda Chem Ind Ltd	Thiazolidine derivative
JPS6051189A (ja) *	1983-08-30	1985-03-22	Sankyo Co Ltd	チアゾリジン誘導体およびその製造法
US4582839A (en) *	1984-03-21	1986-04-15	Takeda Chemical Industries, Ltd.	2,4-thiazolidinediones
CN1003445B (zh) *	1984-10-03	1989-03-01	武田药品工业株式会社	噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) *	1985-06-10	1994-01-05	武田薬品工業株式会社	チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) *	1986-07-24	1989-03-14	Takeda Chemical Industries, Ltd.	Method for producing thiazolidinedione derivatives
ATE186724T1 (de) *	1987-09-04	1999-12-15	Beecham Group Plc	Substituierte thiazolidindionderivate
US4791125A (en) *	1987-12-02	1988-12-13	Pfizer Inc.	Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
FI904414A7 (fi) *	1988-03-08	1990-09-07	Pfizer	Tiatsolidiinidioni-hypoglykeemisesti vaikuttavat aineet
WO1989008651A1 (en) *	1988-03-08	1989-09-21	Pfizer Inc.	Hypoglycemic thiazolidinedione derivatives
GB8919417D0 (en) *	1989-08-25	1989-10-11	Beecham Group Plc	Novel compounds
WO1991007107A1 (en) *	1989-11-13	1991-05-30	Pfizer Inc.	Oxazolidinedione hypoglycemic agents
JPH0469331A (ja) *	1990-07-10	1992-03-04	Asahi Chem Ind Co Ltd	徐放性エマルジョン製剤
JP2572673B2 (ja) *	1990-07-25	1997-01-16	エスエス製薬株式会社	徐放性錠剤
JPH04210683A (ja) *	1990-12-06	1992-07-31	Terumo Corp	チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) *	1991-04-11	1993-02-02	Takeda Chemical Industries, Ltd.	Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
FR2680512B1 (fr) *	1991-08-20	1995-01-20	Adir	Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH06510286A (ja) *	1991-08-26	1994-11-17	ファルマシア・アンド・アップジョン・カンパニー	３−グアニジノプロピオン酸およびピオグリタゾン、グリベンクラミドまたはグリメピリドを含有する医薬組成物
GB9218830D0 (en) *	1992-09-05	1992-10-21	Smithkline Beecham Plc	Novel compounds
US5478853A (en) *	1992-10-12	1995-12-26	Adir Et Compagnie	Thazolidinedione compounds
US5506245A (en) *	1992-10-12	1996-04-09	Adir Et Compagnie	Thiazolidinedione compounds
CA2115587A1 (en) *	1993-02-18	1994-08-19	Hayato Kihara	Styrene copolymers, polystyrene compositions, processes for producing styrene copolymers, and injection-molded articles
DE4317320A1 (de) *	1993-05-25	1994-12-01	Boehringer Mannheim Gmbh	Neue Thiazolidindione und diese enthaltende Arzneimittel
CN1103590C (zh) *	1993-09-15	2003-03-26	三共株式会社	使用噻唑烷二酮防止或延缓非胰岛素依赖性糖尿病(niddm)的发作
US5457109A (en) *	1993-09-15	1995-10-10	Warner-Lambert Company	Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5902726A (en) *	1994-12-23	1999-05-11	Glaxo Wellcome Inc.	Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US5708012A (en) *	1995-04-28	1998-01-13	Sankyo Company, Limited	Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
US5859037A (en) *	1997-02-19	1999-01-12	Warner-Lambert Company	Sulfonylurea-glitazone combinations for diabetes
US6011049A (en) *	1997-02-19	2000-01-04	Warner-Lambert Company	Combinations for diabetes

1998
- 1998-11-12 GB GBGB9824893.3A patent/GB9824893D0/en not_active Ceased
1999
- 1999-11-10 AR ARP990105701A patent/AR029317A1/es unknown
- 1999-11-10 DZ DZ990238A patent/DZ2938A1/xx active
- 1999-11-10 AR ARP990105700A patent/AR029149A1/es unknown
- 1999-11-11 MY MYPI99004899A patent/MY128347A/en unknown
- 1999-11-12 UY UY25797A patent/UY25797A1/es not_active Application Discontinuation
- 1999-11-12 CN CNA2005101201583A patent/CN1771943A/zh active Pending
- 1999-11-12 AU AU17196/00A patent/AU768303B2/en not_active Ceased
- 1999-11-12 KR KR1020017006028A patent/KR20010080440A/ko not_active Ceased
- 1999-11-12 RS YUP-374/01A patent/RS50130B/sr unknown
- 1999-11-12 AT AT99960293T patent/ATE366573T1/de active
- 1999-11-12 SK SK642-2001A patent/SK286357B6/sk not_active IP Right Cessation
- 1999-11-12 BR BR9915284-3A patent/BR9915284A/pt not_active Application Discontinuation
- 1999-11-12 HK HK02101081.6A patent/HK1041202B/en not_active IP Right Cessation
- 1999-11-12 EP EP06124048A patent/EP1759698A1/de not_active Withdrawn
- 1999-11-12 EA EA200700968A patent/EA200700968A1/ru unknown
- 1999-11-12 NZ NZ527132A patent/NZ527132A/en not_active IP Right Cessation
- 1999-11-12 PT PT99960293T patent/PT1135128E/pt unknown
- 1999-11-12 PL PL99349421A patent/PL349421A1/xx not_active Application Discontinuation
- 1999-11-12 DK DK99960293T patent/DK1135128T3/da active
- 1999-11-12 UA UA2001053164A patent/UA79730C2/uk unknown
- 1999-11-12 DE DE69936533T patent/DE69936533T2/de not_active Expired - Lifetime
- 1999-11-12 CA CA002350425A patent/CA2350425C/en not_active Expired - Fee Related
- 1999-11-12 IL IL14308899A patent/IL143088A0/xx unknown
- 1999-11-12 AP AP2005003432A patent/AP2005003432A0/xx unknown
- 1999-11-12 JP JP2000580572A patent/JP2003521455A/ja active Pending
- 1999-11-12 CZ CZ20011656A patent/CZ299801B6/cs not_active IP Right Cessation
- 1999-11-12 EA EA200100539A patent/EA009192B1/ru not_active IP Right Cessation
- 1999-11-12 WO PCT/US1999/026746 patent/WO2000027341A2/en not_active Ceased
- 1999-11-12 KR KR1020077009372A patent/KR20070048279A/ko not_active Ceased
- 1999-11-12 CN CNA2008100058350A patent/CN101244062A/zh active Pending
- 1999-11-12 TR TR2001/01348T patent/TR200101348T2/xx unknown
- 1999-11-12 PE PE1999001148A patent/PE20001239A1/es not_active Application Discontinuation
- 1999-11-12 CN CNB998154806A patent/CN1235586C/zh not_active Expired - Fee Related
- 1999-11-12 HR HR20010344A patent/HRP20010344B1/xx not_active IP Right Cessation
- 1999-11-12 HU HU0104262A patent/HUP0104262A3/hu unknown
- 1999-11-12 CO CO99071567A patent/CO5150158A1/es unknown
- 1999-11-12 ES ES99960293T patent/ES2289833T3/es not_active Expired - Lifetime
- 1999-11-12 EP EP99960293A patent/EP1135128B1/de not_active Expired - Lifetime
- 1999-11-12 AP APAP/P/2001/002137A patent/AP1580A/en active
- 1999-11-12 OA OA00100118A patent/OA12193A/en unknown
- 1999-11-15 UY UY25801A patent/UY25801A1/es not_active Application Discontinuation
- 1999-12-24 TW TW088122851A patent/TWI234456B/zh not_active IP Right Cessation
2001
- 2001-05-10 NO NO20012301A patent/NO328391B1/no not_active IP Right Cessation
- 2001-05-10 ZA ZA200103793A patent/ZA200103793B/en unknown
- 2001-05-11 MA MA26193A patent/MA26759A1/fr unknown
- 2001-06-07 BG BG110061A patent/BG110061A/bg unknown
- 2001-06-07 BG BG105569A patent/BG65577B1/bg unknown
2007
- 2007-09-27 CY CY20071101240T patent/CY1106892T1/el unknown

Also Published As

Publication number	Publication date
CN1354661A (zh)	2002-06-19
HRP20010344A2 (en)	2002-06-30
MY128347A (en)	2007-01-31
TWI234456B (en)	2005-06-21
DE69936533D1 (de)	2007-08-23
CZ20011656A3 (cs)	2002-06-12
MA26759A1 (fr)	2004-12-20
ATE366573T1 (de)	2007-08-15
AR029149A1 (es)	2003-06-18
BR9915284A (pt)	2002-02-13
JP2003521455A (ja)	2003-07-15
SK286357B6 (sk)	2008-08-05
AP1580A (en)	2006-02-24
NZ527132A (en)	2005-01-28
NO20012301D0 (no)	2001-05-10
RS50130B (sr)	2009-03-25
EA200100539A1 (ru)	2001-12-24
HRP20010344B1 (en)	2008-02-29
CA2350425A1 (en)	2000-05-18
OA12193A (en)	2006-05-09
PL349421A1 (en)	2002-07-29
AR029317A1 (es)	2003-06-25
CO5150158A1 (es)	2002-04-29
BG105569A (en)	2002-01-31
DZ2938A1 (fr)	2004-03-15
WO2000027341A3 (en)	2000-09-08
EA009192B1 (ru)	2007-12-28
EP1135128A2 (de)	2001-09-26
PT1135128E (pt)	2007-10-12
EA200700968A1 (ru)	2008-06-30
NO328391B1 (no)	2010-02-08
HK1041202B (en)	2007-10-05
TR200101348T2 (tr)	2002-02-21
NO20012301L (no)	2001-07-09
EP1135128A4 (de)	2003-07-16
BG65577B1 (bg)	2009-01-30
UY25797A1 (es)	2000-12-29
WO2000027341A2 (en)	2000-05-18
AU1719600A (en)	2000-05-29
HUP0104262A3 (en)	2003-06-30
GB9824893D0 (en)	1999-01-06
HUP0104262A2 (en)	2002-08-28
KR20010080440A (ko)	2001-08-22
KR20070048279A (ko)	2007-05-08
YU37401A (sh)	2005-07-19
CN1771943A (zh)	2006-05-17
CA2350425C (en)	2009-06-02
UY25801A1 (es)	2000-08-21
CN1235586C (zh)	2006-01-11
ES2289833T3 (es)	2008-02-01
CZ299801B6 (cs)	2008-11-26
DK1135128T3 (da)	2007-11-05
BG110061A (bg)	2008-12-30
CY1106892T1 (el)	2012-01-25
PE20001239A1 (es)	2000-12-24
CN101244062A (zh)	2008-08-20
EP1135128B1 (de)	2007-07-11
IL143088A0 (en)	2002-11-10
SK6422001A3 (en)	2001-12-03
HK1041202A1 (en)	2002-07-05
AU768303B2 (en)	2003-12-04
AP2005003432A0 (en)	2005-12-31
DE69936533T2 (de)	2008-03-13
ZA200103793B (en)	2002-06-05
EP1759698A1 (de)	2007-03-07

Publication	Publication Date	Title
US20070275063A1 (en)	2007-11-29	Sustained release pharmaceutical compositions and methods of treatment using the same
UA70303C2 (uk)	2004-10-15	Комбінація, що містить тіазолідиндіон, засіб стимуляції секреції інсуліну та дигуанід, спосіб лікування цукрового діабету
KR100680667B1 (ko)	2007-02-09	티아졸리딘디온 및 술포닐우레아를 사용한 당뇨병의 치료
CA2350425C (en)	2009-06-02	Use of an insulin sensitiser for the treatment of type 2 diabetes mellitus
CZ20001298A3 (cs)	2001-08-15	Léčivo pro léčení hyperglykémie a farmaceutický prostředek s obsahem sensitizéru inzulinu
AU2007249132A1 (en)	2008-01-24	Novel method of treatment
AU2757402A (en)	2002-05-16	Novel method of treatment
MXPA01004853A (en)	2002-06-05	Novel method of treatment
HK1101128A (en)	2007-10-12	Novel method of treatment
HRP20000255A2 (en)	2001-02-28	Use of thiazolidinediones for the treatment of hyperglycaemia
UA68352C2 (en)	2004-08-16	Method for treatment of diabetes mellitus with thiazolidin and metformin